Clinical trials: Frown Lines
Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
- Trial name
- READY-3 (NCT04247074)
- Testing
- botulinum toxin neuromodulator
- Where
- 12 sites in United States, Canada
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- Galderma R&D